T1	Intervention 0 30	Evaluation of prostaglandin E1
T2	Intervention 113 201	clinical trial and correlation with plasma suppressive factors for neutrophil activation
T3	Intervention 266 317	prospective, double-blind, placebo-controlled trial
T4	Intervention 364 368	PGE1
T5	Intervention 441 462	Secondary assessments
T6	Intervention 491 495	PGE1
T7	Intervention 666 670	PGE1
T8	Intervention 796 800	PGE1
T9	Intervention 814 821	placebo
T10	Intervention 875 979	assayed by measurement of normal PMN superoxide production relative to normal control plasma (ratio P:C)
T11	Intervention 1025 1029	PGE1
T12	Intervention 1060 1067	placebo
T13	Intervention 1166 1170	PGE1
T14	Intervention 1222 1229	placebo
T15	Intervention 1300 1308	infusion
T16	Intervention 1383 1387	PGE1
T17	Intervention 1574 1578	PGE1
T18	Intervention 1645 1649	PGE1
T19	Intervention 1672 1680	infusion
